Primary Breast Lymphoma: What You Need To Know | MyLymphomaTeam

Connect with others who understand.

sign up Log in
Resources
About MyLymphomaTeam
Powered By

Primary Breast Lymphoma: What You Need To Know

Medically reviewed by Todd Gersten, M.D.
Posted on July 14, 2021

Primary breast lymphoma (PBL) is a type of blood cancer related to myeloma, leukemia, and myeloproliferative neoplasms. In lymphoma, cancer cells originate from lymphocytes, a type of white blood cell. PBL is an extranodal lymphoma — meaning that it occurs outside of lymph nodes or other lymphatic organs — that originates in the breast. PBL does not include lymphomas that have spread to the breast from nearby lymph nodes or other parts of the body, which are called secondary breast lymphomas.

Lymphomas are categorized as either Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). There are five types of Hodgkin lymphoma and more than 60 types of non-Hodgkin lymphoma. PBL is usually aggressive (fast-growing) and usually a type of NHL. Like most NHLs, PBL is usually a type of B-cell lymphoma. B cells are white blood cells that make antibodies.

PBL affects women with a median age of 66 years and almost always occurs in women who are age 50 or older. PBL usually affects the right breast, though sometimes it is bilateral (affects both breasts).

Types of Primary Breast Lymphoma

Primary breast lymphomas are usually B-cell non-Hodgkin lymphomas, but they can be almost any type of lymphoma, including Hodgkin lymphoma. The most commonly seen types of primary breast lymphoma are:

Symptoms of Primary Breast Lymphoma

PBL can have a variety of symptoms, but the most common include:

  • A painless breast lump
  • Swollen lymph nodes (lymphadenopathy), usually the lymph nodes in the armpit on the same side as the tumor
  • Pain in the breast

Other symptoms sometimes seen in PBL and other types of NHL include:

  • B symptoms (unexplained fever, unexplained weight loss, and drenching night sweats)
  • Chest pain or difficulty breathing
  • Abdominal pain, swelling, or bloating
  • Loss of appetite, nausea, and vomiting
  • Itchy skin, sometimes with a rash
  • Fatigue
  • Problems with blood clotting

Diagnosis of Primary Breast Lymphoma

Most cases of PBL present as a lump in the breast and are diagnosed the same way as breast cancer: with a physical exam, medical history, imaging, biopsy, and immunophenotyping of cancer cells. Immunophenotyping entails using advanced laboratory tests to determine what kind of cells are causing a particular cancer.

Imaging

Imaging for breast tumors can involve several tests, which may include:

These tests find the location of potential cancer cells in the breast and other parts of the body.

Biopsy

A biopsy is performed to collect a sample of potential cancer cells for analysis. Breast biopsies usually involve an ultrasound-guided core needle biopsy or fine needle aspiration biopsy. Sometimes an excisional (surgical) biopsy is performed to remove a lump (in a procedure called a lumpectomy) for diagnosis.

Immunophenotyping

Immunophenotyping identifies types of cancer cells based on surface antigens (proteins on the cell surface). Flow cytometry or immunohistochemistry are used to see if specific antibodies will bind to surface antigens. Other techniques, such as in situ hybridization, are used to look for specific genetic mutations in the cancer cells. Pinpointing surface antigens and genetic mutations are important for identifying the type of cancer and for determining which treatments will work best.

Stages of Primary Breast Lymphoma

Lymphomas are staged using the Lugano staging system (based on the older Ann Arbor system). The location of the primary tumor and the cancer’s spread to other parts of the body are used to determine the stage and whether or not the cancer involves extranodal sites (sites outside of lymph nodes or other lymphatic organs). PBL is by definition an extranodal NHL.

There are four stages. Stage 1 and stage 2 are considered early or limited stages. They involve lymph nodes and one organ outside the lymphatic system on the same side of the diaphragm. Stage 3 and stage 4 are late or advanced stages in which the lymphoma has spread to both sides of the diaphragm and may include organs outside of the lymphatic system

The International Prognostic Index (IPI) is also used to assess the outlook of lymphomas. The IPI is based on five factors:

  • Age
  • Lymphoma stage
  • Extranodal involvement
  • Performance status (ability to perform activities of daily living)
  • Blood levels of lactate dehydrogenase (LDH)

Negative prognostic factors that predict higher risk include age over 60 years, advanced-stage disease, involvement of more than one extranodal site, trouble performing daily activities, and high LDH levels.

What Causes Primary Breast Lymphoma?

The cause of PBL and other NHLs is not understood. There are many risk factors for different types of lymphoma, including infection with certain viruses such as Epstein-Barr virus and cytomegalovirus. Having a compromised immune system, such as from HIV, is also associated with lymphoma. BIA-ALCL occurs in people with breast implants, but how breast implants may cause lymphoma is unknown.

Treatment of Primary Breast Lymphoma

Treatment for PBL depends on the type and stage of lymphoma. Generally, PBL is treated like other NHLs with a combination of localized radiation, systemic treatment with chemotherapy, and targeted drug therapy. Surgery such as a mastectomy is sometimes used to remove PBL tumors, but this approach is becoming less common. BIA-ALCL is treated by removing the breast implant and surrounding scar tissue, including the tumor. Removal is sometimes followed by radiation or chemotherapy.

Radiation Therapy

Local radiation is used to treat some types of PBL using focused-beam or external-beam radiation. Radiation can decrease the size of a tumor or kill off cancer cells that remain after surgery.

Chemotherapy

Different types and subtypes of lymphoma respond to different chemotherapy regimens. Some of the most common regimens used for different types of PBL include:

  • R-CHOP — Rituxan (rituximab) with cyclophosphamide (sold as Cytoxan), doxorubicin (also known as hydroxydaunorubicin and sold as Adriamycin), vincristine (formerly sold as Oncovin), and prednisone (a corticosteroid)
  • CHOEP — Cyclophosphamide, doxorubicin, vincristine, VP-16 (etoposide), and prednisone
  • ABVD — Doxorubicin, bleomycin (sold as Blenoxane), vinblastine, and dacarbazine (sold as DTIC-Dome)
  • CODOX — Cyclophosphamide, vincristine sulfate, and doxorubicin
  • R-EPOCH — Rituximab with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin

Targeted Therapy

Targeted therapy with rituximab is used for lymphomas that express the CD20 surface antigen. Rituximab is a monoclonal antibody that binds to CD20 and marks cells for destruction by healthy T cells. Other monoclonal antibody drugs target other cell surface proteins. Targeted therapy can be used alone or in combination with other therapies.

Is Primary Breast Lymphoma a Type of Breast Cancer?

This question is not easy to answer. Perhaps the best way to describe PBL is to say that it is a lymphoma of the breast or a lymphoma in the breast, but not breast cancer. The term “breast cancer” is usually reserved for describing breast carcinomas and sarcomas, so calling a lymphoma in the breast “breast cancer” is not accurate.

People usually use the term “breast cancer” to describe cancers such as invasive ductal carcinoma, which come from cells that are specifically part of breast tissue. But PBL does not come from breast tissue — it comes from lymphocytes that happen to be in breast tissue. Breast implant-associated ALCL, for example, is a lymphoma that, by definition, originates in the breast, but not from breast tissue itself. PBL should not be described as breast cancer, as the term does not best represent the nature of the disease.

Primary Breast Lymphoma Outlook

The outlook for specific cases of PBL depends on the type of lymphoma and what stage it is when it is diagnosed. Limited-stage PBL (stage 1 or 2) has a higher five-year survival rate compared to other limited-stage systemic lymphomas. Overall, the outlook for all types of PBL combined is very good, with a five-year relative survival rate for PBL of 90 percent compared to 76 percent for systemic lymphomas.

PBL survival rates are best for stage 1 disease (greater than 90 percent) and stage 2 disease (greater than 75 percent), but worsen significantly with stage 4 disease, which has a survival rate of less than 45 percent.

The different lymphoma subtypes of PBL can have very different outlooks. The five-year relative survival rate of stage 1 and 2 PBL is as high as 100 percent for follicular lymphoma, 95 percent for marginal zone lymphoma, 78 percent for diffuse large B-cell lymphoma, and 74 percent for anaplastic large cell lymphoma.

Talk With Others Who Understand

MyLymphomaTeam is the social network for people with lymphoma and their loved ones. On MyLymphomaTeam, more than 8,000 members come together to ask questions, give advice, and share their stories with others who understand life with lymphoma.

Are you or someone you care for living with primary breast lymphoma? Share your experience in the comments below, or start a conversation by posting on your Activities page.

References
  1. Primary Breast Lymphoma — Journal of Surgical Case Reports
  2. Lymphoma — Non-Hodgkin: Subtypes — American Society of Clinical Oncology
  3. Primary Breast Lymphoma in the United States: 1975–2013 — Journal of the National Cancer Institute
  4. What’s New on Primary Hodgkin’s Lymphoma of the Breast? A Case Report and Review of the Literature — International Journal of Surgery Case Reports
  5. What Is Lymphoma? — Lymphoma Research Foundation
  6. Mammogram Basics — American Cancer Society
  7. Breast Ultrasound — American Cancer Society
  8. Computed Tomography (CT) Scan — Johns Hopkins Medicine
  9. Positron Emission Tomography (PET) — Johns Hopkins Medicine
  10. Magnetic Resonance Imaging (MRI) — Johns Hopkins Medicine
  11. Breast Biopsy — Mayo Clinic
  12. Breast Biopsy — American Cancer Society
  13. Fluorescence In Situ Hybridization (FISH) — National Human Genome Research Institute
  14. Non-Hodgkin Lymphoma Stages — American Cancer Society
  15. Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma — American Cancer Society
  16. What Causes Non-Hodgkin Lymphoma? — American Cancer Society
  17. Understanding Non-Hodgkin Lymphoma — Lymphoma Research Foundation
  18. What is BIA-ALCL? — Breastcancer.org
  19. Treating Non-Hodgkin Lymphoma — American Cancer Society
  20. Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) — Food and Drug Administration
  21. Radiation Therapy for Non-Hodgkin Lymphoma — American Cancer Society
  22. Chemotherapy for Non-Hodgkin Lymphoma — American Cancer Society
  23. Clinical Characteristics and Outcomes of Primary Breast Lymphoma: The Cleveland Clinic Experience — Cureus Journal of Medical Science
  24. Understanding Targeted Therapy — American Society of Clinical Oncology
  25. Cancer Classification — National Cancer Institute
  26. What Is Cancer? — American Society of Clinical Oncology
  27. Adenocarcinoma — Cancer Treatment Centers of America
  28. What is Lymphoma? — Lymphoma Action
  29. Types of Breast Cancer — American Cancer Society
Posted on July 14, 2021
All updates must be accompanied by text or a picture.

Become a Subscriber

Get the latest articles about lymphoma sent to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Todd Gersten, M.D. is a hematologist-oncologist at the Florida Cancer Specialists & Research Institute in Wellington, Florida. Review provided by VeriMed Healthcare Network. Learn more about him here.
Kristopher Bunting, M.D. studied chemistry and life sciences at the U.S. Military Academy, West Point, and received his doctor of medicine degree from Tulane University. Learn more about him here.

Related Articles

There are many risk factors, both inherited and environmental, believed to increase one’s risk of...

Is Diffuse Large B-Cell Lymphoma Inherited? Genetics and 8 Other Risk Factors

There are many risk factors, both inherited and environmental, believed to increase one’s risk of...
The majority of people with diffuse large B-cell lymphoma (DLBCL) will live with their condition ...

DLBCL Prognosis: Fear, Hope, and Understanding Survival Rates

The majority of people with diffuse large B-cell lymphoma (DLBCL) will live with their condition ...
Double-hit lymphoma (DHL) is an aggressive cancer that develops from white blood cells called B l...

Double-Hit Lymphoma in DLBCL: Symptoms, Survival Rate, and More

Double-hit lymphoma (DHL) is an aggressive cancer that develops from white blood cells called B l...
B-cell lymphoma, also called B-cell non-Hodgkin lymphoma, is a type of blood cancer that develops...

12 Types of B-Cell Lymphoma and Subtypes of DLBCL

B-cell lymphoma, also called B-cell non-Hodgkin lymphoma, is a type of blood cancer that develops...
Shouldn’t “cured” mean you’ll stay healthy? Although Hodgkin lymphoma (formerly called Hodgkin’s ...

7 Complications of Hodgkin Lymphoma

Shouldn’t “cured” mean you’ll stay healthy? Although Hodgkin lymphoma (formerly called Hodgkin’s ...
Colorectal lymphoma, a rare type of colon cancer, can be tough to pinpoint. Its symptoms may be m...

Colorectal Lymphoma: Causes, Symptoms, and Treatment

Colorectal lymphoma, a rare type of colon cancer, can be tough to pinpoint. Its symptoms may be m...

Recent Articles

Diffuse large B-cell lymphoma (DLBCL) is staged based on which lymph nodes and organs are involve...

Early vs. Advanced DLBCL: How Are They Treated Differently?

Diffuse large B-cell lymphoma (DLBCL) is staged based on which lymph nodes and organs are involve...
Roughly 50 percent to 60 percent of people relapse within the first two years of achieving remiss...

DLBCL Relapse Chances and Treatment Options

Roughly 50 percent to 60 percent of people relapse within the first two years of achieving remiss...
After successful treatment for diffuse large B-cell lymphoma (DLBCL), you’ll enter complete remis...

DLBCL Relapse: 4 Symptoms To Watch For

After successful treatment for diffuse large B-cell lymphoma (DLBCL), you’ll enter complete remis...
When treatment for diffuse large B-cell lymphoma (DLBCL) successfully kills all of your detectabl...

Remission and Complete Response in DLBCL: How Long It Lasts and More

When treatment for diffuse large B-cell lymphoma (DLBCL) successfully kills all of your detectabl...
The first treatment given for diffuse large B-cell lymphoma (DLBCL) is usually a drug combination...

R-CHOP Treatment for DLBCL: 5 Facts and What To Expect

The first treatment given for diffuse large B-cell lymphoma (DLBCL) is usually a drug combination...
Welcome to MyLymphomaTeam — the place to connect with others living with lymphoma. This video wi...

Getting Started on MyLymphomaTeam (VIDEO)

Welcome to MyLymphomaTeam — the place to connect with others living with lymphoma. This video wi...
MyLymphomaTeam My lymphoma Team

Thank you for subscribing!

Become a member to get even more:

sign up for free

close